Rhode Island House Health Committee advances multiple health bills to House floor

The House Committee on Health and Human Services met June 12 in Room 101 of the State House and voted to advance multiple health-related measures to the House floor.

The committee approved H5615 Sub A, a Department of Health–driven change to opioid prescribing statutes that among other edits replaces the term "medicine" with "medications," removes a director-maintained list, limits an initial opioid prescription to a seven-day supply and caps opioid prescriptions to minors at 20 doses with a required conversation with a parent or guardian. Committee counsel said those changes came at the Department's request. The committee approved H5615 Sub A on a roll-call vote, which the clerk announced as 11–2.

Separately, the committee approved H5351 Sub A, which tightens the statutory definition of "cosmetic medical procedure," adds a statutory definition for "certified nurse practitioner," defines a "delegate" (licensed nonphysician) who may perform certain cosmetic services, narrows vendor-led training so it cannot be the sole training source, and allows medical directors for medical spas to be on-site or off-site. The chair moved a substitution and the committee approved the substitute by roll-call (announced as 11–1); the substitute was then voted out by roll call with the same announced tally.

The committee also approved H5614 (a Department of Health technical alignment with federal requirements) by voice/roll call (announced 13–0) and H6244 Sub A, a provision that places a prohibition in patient-rights language preventing health-care facility personnel from asking patients about immigration status or requesting proof of legal presence (counsel noted Sub A mirrors a Senate companion). The clerk announced the H6244 Sub A vote as 13–0.

H5120 Sub A, a three-year pilot to exempt in-network primary care providers from prior authorization for services they order, passed after counsel described the bill's reporting requirements. The pilot would begin Oct. 1, 2025, and sunset Oct. 1, 2028; insurers must provide an annual report by July 1 and OHIC is directed to promulgate rules by Jan. 1, 2026 and to oversee an existing work group. The committee approved H5120 Sub A by roll call (announced 13–0).

The committee also voted to advance H5023 Sub A, which establishes a rare disease advisory council and (per counsel) removes prior funding language and a restricted-receipt account; that substitute passed by roll call (announced 13–0).

Procedurally, the committee voted to hold the remaining bills on the calendar for further study (a non-substantive motion), a motion that the clerk recorded as passing 11–2. That motion specifically held HB6384 and SB680 Sub A for further study; the committee later proceeded to hear SB680 Sub A.

Votes at a glance (announced tallies in committee): H5615 Sub A — passed, 11–2; H5351 Sub A — passed, 11–1; H5614 — passed, 13–0; H6244 Sub A — passed, 13–0; H5120 Sub A — passed, 13–0; H5023 Sub A — passed, 13–0; procedural motion to hold remaining bills — passed, 11–2.

What this means: Most of the measures the committee considered were reported out for consideration by the full House. Several were described by counsel as technical or as efforts to strike a balance between proponents and opponents; others (notably the opioid initial-prescription limit and the prior-authorization pilot) include concrete, operational changes staff and regulated entities will have to implement.

The committee adjourned after concluding scheduled testimony and procedural business. The bills that passed will be scheduled for floor action according to House rules and the House calendar.

Sources: Committee counsel explanations and roll-call votes recorded on the committee transcript for the June 12, 2025 House Committee on Health and Human Services meeting.